Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.85 |
| ▸ | LMNA | P02545 | 1/20 | 0.85 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.51 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6759604 | 1.00 | SMN1; SMN2 (0.85) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL21071132 | 1.00 | SMN1; SMN2 (0.85) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL21069619 | 1.00 | SMN1; SMN2 (0.85) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL1699791 | 0.98 | SMN1; SMN2 (0.88) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL30823376 | 0.94 | SMN1; SMN2 (0.97) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL7372302 | 0.92 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL30980740 | 0.92 | SMN1; SMN2 (0.81) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL5529923 | 0.89 | LMNA (0.68) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL25597409 | 0.88 | SMN1; SMN2 (0.85) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL18886422 | 0.87 | SMN1; SMN2 (0.83) | SMN1; SMN2LMNAHTTL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12544448-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-12403198-B2 | Benzimidazole thiophene derivative compounds inducing selective degradation of PLK1 | UPPTHERA (KR) | 2025-09-02 | — | — | US | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250215042-A1 | MANNOSE-TARGETED COMPOSITIONS | GENEVANT SCIENCES GMBH (CH) | 2025-07-03 | — | — | US | disclosed |
| US-20250108117-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-04-03 | — | — | US | disclosed |
| US-12263165-B2 | Small molecule inhibitors of cancer stem cells and mesenchymal cancer types | THE SCRIPPS RESEARCH INSTITUTE (US) | 2025-04-01 | — | — | US | disclosed |
| US-20250064944-A1 | MULTIVALENT CARGO-CARRYING COMPLEXES AND USES THEREOF | ASTRAZENECA AB (SE) | 2025-02-27 | — | — | US | disclosed |
| WO-2025021829-A1 | MULTIVALENT CARGO-CARRYING COMPLEXES AND USES THEREOF | ASTRAZENECA AB (SE) | 2025-01-30 | — | — | WO | disclosed |
| US-11318205-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-20220062323-A1 | BIVALENT TARGETED CONJUGATES | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-03-03 | — | — | US | disclosed |
| US-20220062323-A1 | BIVALENT TARGETED CONJUGATES | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-03-03 | — | — | US | disclosed |
| US-20220031847-A1 | THERAPEUTIC METHODS | GENEVANT SCIENCES GMBH (CH) | 2022-02-03 | — | — | US | disclosed |
| WO-2021162493-A1 | PROTEIN KINASE DEGRADATION INDUCING COMPOUND, AND USE THEREOF | 보로노이 주식회사 | 2021-08-19 | — | — | WO | disclosed |
| CN-113226332-A | Bivalent targeting conjugates | 阿布特斯生物制药公司 | 2021-08-06 | — | — | CN | disclosed |
| US-10874743-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| EP-3731869-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| EP-3501546-A2 | CYSTEINE DRUG CONJUGATES AND USE OF SAME | Seattle Genetics, Inc. (US) | 2019-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874743-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | SMN1; SMN2 2647/4885LMNA 1656/4885HTT 2464/4885 |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SMN1; SMN2 2647/4885LMNA 1656/4885HTT 2464/4885 |
| US-12263165-B2 | Small molecule inhibitors of cancer stem cells and mesenchymal cancer types | VIM, CDH1, BRCA1 | SMN1; SMN2 1938/4885LMNA 2434/4885HTT 3391/4885 |
| US-20250108117-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | MTOR, RICTOR, RPTOR | SMN1; SMN2 2014/4885LMNA 2837/4885HTT 1420/4885 |
| US-20220062323-A1 | BIVALENT TARGETED CONJUGATES | ERBB2, PCNA, MRE11 | SMN1; SMN2 1422/4885LMNA 1950/4885HTT 2221/4885 |
| US-20250064944-A1 | MULTIVALENT CARGO-CARRYING COMPLEXES AND USES THEREOF | SNRPE, EXOSC5, DIS3 | SMN1; SMN2 1118/4885LMNA 2189/4885HTT 640/4885 |
| US-20250215042-A1 | MANNOSE-TARGETED COMPOSITIONS | MAN2A1, M6PR, MANBA | SMN1; SMN2 931/4885LMNA 705/4885HTT 2433/4885 |
| US-20220031847-A1 | THERAPEUTIC METHODS | NUP205, HNRNPH3, FUS | SMN1; SMN2 358/4885LMNA 64/4885HTT 706/4885 |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SMN1; SMN2 2647/4885LMNA 1656/4885HTT 2464/4885 |
| US-12403198-B2 | Benzimidazole thiophene derivative compounds inducing selective degradation of PLK1 | PLK1, BUB1, BUB1B | SMN1; SMN2 3569/4885LMNA 3138/4885HTT 2214/4885 |
| US-12544448-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | RICTOR, MTOR, MLST8 | SMN1; SMN2 1662/4885LMNA 2304/4885HTT 2496/4885 |
| US-11318205-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | SMN1; SMN2 2647/4885LMNA 1656/4885HTT 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.